Do Myoepithelial Cells Hold the Key for Breast Tumor Progression?

Journal of Mammary Gland Biology and Neoplasia

Volumn 10, Issue 3, 2005, Pages 231-247

  Polyak, Kornelia ^a,b   Hu, Min ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

DCIS (ductal carcinoma in situ); myoepithelium; paracrine factor; SAGE (serial analysis of gene expression); tumor progression

Indexed keywords

BREAST TUMOR; CARCINOMA IN SITU; CELL TRANSFORMATION; CHEMISTRY; DISEASE COURSE; EPITHELIUM; EPITHELIUM CELL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; MAMMARY GLAND; METABOLISM; MUSCLE CELL; PAGET NIPPLE DISEASE; PATHOLOGY; PHYSIOLOGY; REVIEW; TUMOR CELL LINE;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPITHELIAL CELLS; EPITHELIUM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MAMMARY GLANDS, HUMAN; MUSCLE CELLS;

EID: 33747095513     PISSN: 10833021     EISSN: 15737039     Source Type: Journal    
DOI: 10.1007/s10911-005-9584-6     Document Type: Article

References (92)

1. Nevins JR, Huang ES, Dressman H, Pittman J, Huang AT, West M. Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum Mol Genet 2003;12(Spec No 2):R153–7. DOI: 10.1093/hmg/ddg287
2. Shekhar MP, Pauley R, Heppner G. Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res 2003;5:130–5. DOI: 10.1186/bcr580
3. Kenny PA, Bissell MJ. Tumor reversion: correction of malignant behavior by microenvironmental cues. Int J Cancer 2003;107:688–95. DOI: 10.1002/ijc.11491
4. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW. The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 2002;70:537–46. DOI: 10.1046/j.1432-0436.2002.700907.x
5. Radisky D, Hagios C, Bissell MJ. Tumors are unique organs defined by abnormal signaling and context. Semin Cancer Biol 2001;11:87–95. DOI: 10.1006/scbi.2000.0360
6. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860–7. DOI: 10.1038/nature01322
7. Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science 2002;296:1046–9. DOI: 10.1126/science.1067431
8. Tlsty TD. Stromal cells can contribute oncogenic signals. Semin Cancer Biol 2001;11:97–104. DOI: 10.1006/scbi.2000.0361
9. Tlsty TD, Hein PW. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 2001;11:54–9. DOI: 10.1016/S0959-437X(00)00156-8
10. DeCosse JJ, Gossens CL, Kuzma JF, Unsworth BR. Breast cancer: induction of differentiation by embryonic tissue. Science 1973;181:1057–8.
11. DeCosse JJ, Gossens C, Kuzma JF, Unsworth BR. Embryonic inductive tissues that cause histologic differentiation of murine mammary carcinoma in vitro. J Natl Cancer Inst 1975;54:913–22.
12. Rohan RM, Fernandez A, Udagawa T, Yuan J, D’Amato RJ. Genetic heterogeneity of angiogenesis in mice. Faseb J 2000;14:871–6.
13. Hunter KW. Host genetics and tumour metastasis. Br J Cancer 2004;90:752–5. DOI: 10.1038/sj.bjc.6601590
14. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004;303:848–51. DOI: 10.1126/science.1090922
15. Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, et al. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene 2005;24(32):5053–68. DOI: 10.1038/sj.onc.1208685
16. Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C. The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci. 2004;117:1495–502. DOI: 10.1242/jcs.01000
17. Medina D, Kittrell F. Stroma is not a major target in DMBA-mediated tumorigenesis of mouse mammary preneoplasia. J Cell Sci 2005;118(Pt 1):123–7. DOI: 10.1242/jcs.01597
18. Gudjonsson T, Ronnov-Jessen L, Villadsen R, Rank F, Bissell MJ, Petersen OW. Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J Cell Sci 2002;115(Pt 1):39–50.
19. Sternlicht MD, Barsky SH. The myoepithelial defense: a host defense against cancer. Med Hypotheses 1997;48:37–46. DOI: 10.1016/S0306-9877(97)90022-0
20. Sternlicht MD, Kedeshian P, Shao ZM, Safarians S, Barsky SH. The human myoepithelial cell is a natural tumor suppressor. Clin Cancer Res 1997;3:1949–58.
21. Deugnier MA, Teuliere J, Faraldo MM, Thiery JP, Glukhova MA. The importance of being a myoepithelial cell. Breast Cancer Res 2002;4:224–30. DOI: 10.1186/bcr459
22. Elenbaas B, Weinberg RA. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 2001;264:169–84. DOI: 10.1006/excr.2000.5133
23. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 2003;3:695–701. DOI: 10.1038/nrc1165
24. Lakhani SR, O’Hare MJ. The mammary myoepithelial cell—Cinderella or ugly sister? Breast Cancer Res 2001;3:1–4. DOI: 10.1186/bcr260
25. Barbareschi M, Pecciarini L, Cangi MG, Macri E, Rizzo A, Viale G, et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 2001;25:1054–60. DOI: 10.1097/00000478-200108000-00010
26. Santini D, Ceccarelli C, Tardio ML, Taffurelli M, Marrano D. Immunocytochemical expression of epidermal growth factor receptor in myoepithelial cells of the breast. Appl Immunohistochem Mol Morphol 2002;10:29–33. DOI: 10.1097/00022744-200203000-00005
27. Yaziji H, Gown AM, Sneige N. Detection of stromal invasion in breast cancer: the myoepithelial markers. Adv Anat Pathol 2000;7:100–9. DOI: 10.1097/00125480-200007020-00005
28. Barsky SH. Myoepithelial mRNA expression profiling reveals a common tumor-suppressor phenotype. Exp Mol Pathol 2003;74:113–22. DOI: 10.1016/S0014-4800(03)00011-X
29. Page MJ, Amess B, Townsend RR, Parekh R, Herath A, Brusten L, et al. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci U S A 1999;96:12589–94. DOI: 10.1073/pnas.96.22.12589
30. Porter DA, Krop IE, Nasser S, Sgroi D, Kaelin CM, Marks JR, et al. A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res 2001;61:5697–702.
31. Jones C, Mackay A, Grigoriadis A, Cossu A, Reis-Filho JS, Fulford L, et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 2004;64:3037–45. DOI: 10.1158/0008-5472.CAN-03-2028
32. Baik I, Becker PS, DeVito WJ, Lagiou P, Ballen K, Quesenberry PJ, et al. Stem cells and prenatal origin of breast cancer. Cancer Causes Control 2004;15:517–30. DOI: 10.1023/B:CACO.0000036450.06092.ce
33. Trichopoulos D. Intrauterine environment, mammary gland mass and breast cancer risk. Breast Cancer Res 2003;5:42–4. DOI: 10.1186/bcr555
34. Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin’s disease. Cancer Treat Rev 2000;26:291–302. DOI: 10.1053/ctrv.2000.0174
35. Hildreth NG, Shore RE, Dvoretsky PM. The risk of breast cancer after irradiation of the thymus in infancy. N Engl J Med 1989;321:1281–4. DOI: 10.1056/NEJM198911093211901
36. Osin PP, Anbazhagan R, Bartkova J, Nathan B, Gusterson BA. Breast development gives insights into breast disease. Histopathology 1998;33:275–83. DOI: 10.1046/j.1365-2559.1998.00479.x
37. Anbazhagan R, Osin PP, Bartkova J, Nathan B, Lane EB, Gusterson BA. The development of epithelial phenotypes in the human fetal and infant breast. J Pathol 1998;184:197–206. DOI: 10.1002/(SICI)1096-9896(199802)184:2<197::AID-PATH992>3.0.CO;2-J
38. Naccarato AG, Viacava P, Vignati S, Fanelli G, Bonadio AG, Montruccoli G, et al. Bio-morphological events in the development of the human female mammary gland from fetal age to puberty. Virchows Arch 2000;436:431–8. DOI: 10.1007/s004280050470
39. Jolicoeur F, Gaboury LA, Oligny LL. Basal cells of second trimester fetal breasts: immunohistochemical study of myoepithelial precursors. Pediatr Dev Pathol 2003;6:398–413. DOI: 10.1007/s10024-003-1125-y
40. Zhang RR, Man YG, Vang R, Saenger JS, Barner R, Wheeler DT, et al. A subset of morphologically distinct mammary myoepithelial cells lacks corresponding immunophenotypic markers. Breast Cancer Res 2003;5:R151–6. DOI: 10.1186/bcr635
41. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004;6:R605–15. DOI: 10.1186/bcr920
42. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. in vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003;17:1253–70. DOI: 10.1101/gad.1061803
43. Hoogerbrugge N, Bult P, de Widt-Levert LM, Beex LV, Kiemeney LA, Ligtenberg MJ, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 2003;21:41–5. DOI: 10.1200/JCO.2003.02.137
44. Adem C, Jenkins RB, Capron F, Stoppa-Lyonnet D. High-risk lesions in high-risk women: a high-risk formalin-based biology. J Clin Oncol 2004;22:1159–61; author reply 1161–2.
45. James LA, Mitchell EL, Menasce L, Varley JM. Comparative genomic hybridisation of ductal carcinoma in situ of the breast: identification of regions of DNA amplification and deletion in common with invasive breast carcinoma. Oncogene 1997;14:1059–65. DOI: 10.1038/sj.onc.1200923
46. Waldman FM, DeVries S, Chew KL, Moore DH, 2nd, Kerlikowske K, Ljung BM. Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Natl Cancer Inst 2000;92:313–20. DOI: 10.1093/jnci/92.4.313
47. Aubele M, Mattis A, Zitzelsberger H, Walch A, Kremer M, Welzl G, et al. Extensive ductal carcinoma in situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH. Int J Cancer 2000;85:82–6. DOI: 10.1002/(SICI)1097-0215(20000101)85:1<82::AID-IJC15>3.0.CO;2-S
48. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol 2005;205:248–54. DOI: 10.1002/path.1691
49. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004;96:906–20. DOI: 10.1093/jnci/djh164
50. Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980–2001. Cancer Epidemiol Biomarkers Prev 2005;14:1008–11. DOI: 10.1158/1055-9965.EPI-04-0849
51. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med 2004;350:1430–41. DOI: 10.1056/NEJMra031301
52. Damiani S, Ludvikova M, Tomasic G, Bianchi S, Gown AM, Eusebi V. Myoepithelial cells and basal lamina in poorly differentiated in situ duct carcinoma of the breast. An immunocytochemical study. Virchows Arch 1999;434:227–34. DOI: 10.1007/s004280050332
53. Tobacman JK. Filament disassembly and loss of mammary myoepithelial cells after exposure to lambda-carrageenan. Cancer Res 1997;57:2823–6.
54. Nguyen M, Lee MC, Wang JL, Tomlinson JS, Shao ZM, Alpaugh ML, et al. The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype. Oncogene 2000;19:3449–59. DOI: 10.1038/sj.onc.1203677
55. Shao ZM, Nguyen M, Alpaugh ML, O’Connell JT, Barsky SH. The human myoepithelial cell exerts antiproliferative effects on breast carcinoma cells characterized by p21WAF1/CIP1 induction, G2/M arrest, and apoptosis. Exp Cell Res 1998;241:394–403. DOI: 10.1006/excr.1998.4066
56. Sternlicht MD, Safarians S, Calcaterra TC, Barsky SH. Establishment and characterization of a novel human myoepithelial cell line and matrix-producing xenograft from a parotid basal cell adenocarcinoma. In Vitro Cell Dev Biol Anim 1996;32:550–63.
57. Jones JL, Shaw JA, Pringle JH, Walker RA. Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells. J Pathol 2003;201:562–72. DOI: 10.1002/path.1483
58. Shao ZM, Radziszewski WJ, Barsky SH. Tamoxifen enhances myoepithelial cell suppression of human breast carcinoma progression in vitro by two different effector mechanisms. Cancer Lett 2000;157:133–44. DOI: 10.1016/S0304-3835(00)00466-3
59. Chi A, Chen X, Chirala M, Younes M. Differential expression of estrogen receptor beta isoforms in human breast cancer tissue. Anticancer Res 2003;23:211–6.
60. Tobacman JK, Hinkhouse M, Khalkhali-Ellis Z. Steroid sulfatase activity and expression in mammary myoepithelial cells. J Steroid Biochem Mol Biol 2002;81:65–8. DOI: 10.1016/S0960-0760(02)00048-1
61. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90:1138–45. DOI: 10.1093/jnci/90.15.1138
62. Kurose K, Hoshaw-Woodard S, Adeyinka A, Lemeshow S, Watson PH, Eng C. Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. Hum Mol Genet 2001;10:1907–13. DOI: 10.1093/hmg/10.18.1907
63. Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavassoli FA. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res 2000;60:2562–6.
64. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 2002;32:355–7. DOI: 10.1038/ng1013
65. Larson PS, de las Morenas A, Bennett SR, Cupples LA, Rosenberg CL. Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas. Am J Pathol 2002;161:283–90.
66. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 1996;274:2057–9. DOI: 10.1126/science.274.5295.2057
67. Fukino K, Shen L, Matsumoto S, Morrison CD, Mutter GL, Eng C. Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets. Cancer Res 2004;64:7231–6. DOI: 10.1158/0008-5472.CAN-04-2866
68. Dietrich CU, Pandis N, Teixeira MR, Bardi G, Gerdes AM, Andersen JA, et al. Chromosome abnormalities in benign hyperproliferative disorders of epithelial and stromal breast tissue. Int J Cancer 1995;60:49–53.
69. Iqbal M, Shoker BS, Foster CS, Jarvis C, Sibson DR, Davies MP. Molecular and genetic abnormalities in radial scar. Hum Pathol 2002;33:715–22. DOI: 10.1053/hupa.2002.125375
70. Lakhani SR, Chaggar R, Davies S, Jones C, Collins N, Odel C, et al. Genetic alterations in ‘normal’ luminal and myoepithelial cells of the breast. J Pathol 1999;189:496–503. DOI: 10.1002/(SICI)1096-9896(199912)189:4<496::AID-PATH485>3.0.CO;2-D
71. Peyrol S, Raccurt M, Gerard F, Gleyzal C, Grimaud JA, Sommer P. Lysyl oxidase gene expression in the stromal reaction to in situ and invasive ductal breast carcinoma. Am J Pathol 1997;150(2):497–507.
72. Stephenson JM, Banerjee S, Saxena NK, Cherian R, Banerjee SK. Neuropilin-1 is differentially expressed in myoepithelial cells and vascular smooth muscle cells in preneoplastic and neoplastic human breast: a possible marker for the progression of breast cancer. Int J Cancer 2002;101:409–14. DOI: 10.1002/ijc.10611
73. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004;6:17–32. DOI: 10.1016/j.ccr.2004.06.010
74. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1:46–54. DOI: 10.1038/35094059
75. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335–48. DOI: 10.1016/j.cell.2005.02.034
76. Hu M, Yao J, Cai L, Bachman KE, van den Brule F, Velculescu V, et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005;37:899–905. DOI: 10.1038/ng1596
77. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005;5:223–31. DOI: 10.1038/nrc1571
78. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143–53. DOI: 10.1038/nrc1279
79. Bell AC, Felsenfeld G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 2000;405:482–5. DOI: 10.1038/35013100
80. Shao ZM, Nguyen M, Barsky SH. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 2000;19:4337–45. DOI: 10.1038/sj.onc.1203785
81. Ronnov-Jessen L, Petersen OW, Koteliansky VE, Bissell MJ. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 1995;95:859–73. DOI: 10.1172/JCI117736
82. Direkze NC, Forbes SJ, Brittan M, Hunt T, Jeffery R, Preston SL, et al. Multiple organ engraftment by bone-marrow-derived myofibroblasts and fibroblasts in bone-marrow-transplanted mice. Stem Cells 2003;21:514–20. DOI: 10.1634/stemcells.21-5-514
83. Brittan M, Hunt T, Jeffery R, Poulsom R, Forbes SJ, Hodivala-Dilke K, et al. Bone marrow derivation of pericryptal myofibroblasts in the mouse and human small intestine and colon. Gut 2002;50:752–7. DOI: 10.1136/gut.50.6.752
84. Russo J, Russo IH. Atlas and histologic classification of tumors of the rat mammary gland. J Mammary Gland Biol Neoplasia 2000;5:187–200. DOI: 10.1023/A:1026443305758
85. Boland GP, Knox WF, Bundred NJ. Molecular markers and therapeutic targets in ductal carcinoma in situ. Microsc Res Tech 2002;59:3–11. DOI: 10.1002/jemt.10172
86. Miller F. Xenograft models of premalignant breast disease. J Mammary Gland Biol Neoplasia 2000;5:379–91. DOI: 10.1023/A:1009577811584
87. Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ [letter]. J Natl Cancer Inst 2000;92:1185–6. DOI: 10.1093/jnci/92.14.1185A
88. Tait L, Dawson PJ, Wolman SR, Galea K, Miller FR. Multipotent human breast stem cell line MCF10AT. Int J Oncol 1996;9:263–67.
89. Barsky SH, Doberneck SA, Sternlicht MD, Grossman DA, Love SM. ‘Revertant’ DCIS in human axillary breast carcinoma metastases. J Pathol 1997;183:188–94. DOI: 10.1002/(SICI)1096-9896(199710)183:2<188::AID-PATH898>3.0.CO;2-7
90. Laakso M, Loman N, Borg A, Isola J. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 2005.
91. Steele VE, Hawk ET, Viner JL, Lubet RA. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res 2003;523–24:137–44.
92. Man YG, Tai L, Barner R, Vang R, Saenger JS, Shekitka KM, et al. Cell clusters overlying focally disrupted mammary myoepithelial cell layers and adjacent cells within the same duct display different immunohistochemical and genetic features: implications for tumor progression and invasion. Breast Cancer Res 2003;5(6):R231–41. DOI: 10.1186/bcr653